Overview

Vilon is a dipeptide bioregulator composed of lysine and glutamic acid, developed as part of the peptide bioregulator research pioneered by Professor Vladimir Khavinson. This synthetic peptide has demonstrated significant biological activity in preclinical studies, particularly in the areas of aging, gene expression modulation, and cellular function restoration.

Research indicates that Vilon may work through epigenetic mechanisms, specifically by inducing chromatin reactivation in aged cells. Studies have shown its potential to influence transforming growth factor-beta content, affect microvessel permeability, and demonstrate anti-tumor properties in various animal models.

The peptide represents part of a broader class of bioregulators that may support healthy aging processes through molecular-level interventions in cellular function and gene expression patterns.

Mechanism of Action

Vilon appears to exert its effects through several interconnected mechanisms:

Chromatin Reactivation: Research suggests Vilon can reactivate chromatin in cultured lymphocytes from elderly individuals, potentially restoring more youthful gene expression patterns. This epigenetic modification may be central to its anti-aging properties.

Gene Expression Modulation: Studies using DNA microarray technology have demonstrated that Vilon influences gene expression in heart tissue, suggesting broad regulatory effects on cellular function.

Growth Factor Regulation: Animal studies indicate Vilon affects transforming growth factor-beta (TGF-β) content and microvessel permeability, which may contribute to its tissue-protective effects.

Anti-apoptotic Effects: Research suggests the peptide may inhibit programmed cell death, potentially supporting cellular longevity and function.

The dipeptide structure allows for relatively easy absorption and distribution, while its specific amino acid sequence appears to trigger cascading effects on cellular regulation and function.

Research Summary

Vilon has been studied in 10 published papers and 1 clinical trial, with research spanning over two decades. The evidence base consists primarily of preclinical animal studies with some human cell culture work.

Key Studies

Longevity Research (2000): A foundational study published in the Bulletin of Experimental Biology and Medicine examined Vilon's effects on biological age and lifespan in mice. Results suggested potential life-extending properties, though specific numerical data varies by study protocol.

Chromatin Studies (2004, 2006, 2023): Multiple publications have documented Vilon's ability to reactivate chromatin in aged cells. A 2004 Biogerontology study specifically demonstrated chromatin reactivation in cultured lymphocytes from elderly humans, while more recent 2023 research has explored epigenetic modifications under peptide bioregulator influence.

Cardiovascular Research (2002): DNA microarray analysis of mouse heart tissue showed that Vilon influences gene expression patterns, suggesting potential cardiovascular benefits, though the clinical significance remains to be established.

Renal Function (2005): Animal studies indicated Vilon may affect TGF-β content and microvessel permeability during experimental chronic renal failure, suggesting potential nephroprotective properties.

Cancer Research (2001, 2003): Studies have examined Vilon's effects on tumor development, including bladder tumors in rats and combined effects with chemotherapy agents. Results suggested potential anti-tumor properties, though this research is preliminary.

Human Data

Limited human data exists, primarily from cell culture studies using lymphocytes from elderly volunteers. One clinical trial (NCT02580799) was registered but appears unrelated to Vilon's primary mechanisms of action.

Dosage Guidelines

Dosage recommendations are based on animal research and anecdotal reports, as human clinical trials establishing optimal dosing are not available.

Subcutaneous Protocol:

• 1-5 mg injected subcutaneously
• Rotate injection sites
• 10-20 day cycles with 10-day breaks

Oral Protocol:

• 5-10 mg taken on empty stomach
• Morning administration preferred
• Similar cycling pattern to injection

Cycle Recommendations: Most research protocols used intermittent administration rather than continuous dosing. Common approaches include 10 days on, 10 days off, or 20 days on, 10 days off.

Safety Profile

Vilon's safety profile in humans is not well-established due to limited clinical research. Animal studies have not reported significant adverse effects at research doses.

Reported Side Effects

• No consistent side effects documented in animal studies
• Human safety data insufficient for comprehensive assessment
• Theoretical concerns based on mechanism of action

Contraindications

• Active malignancy: Due to potential effects on cell growth and chromatin reactivation
• Pregnancy and breastfeeding: Unknown effects on fetal development
• Pediatric use: No safety data in developing individuals
• Autoimmune conditions: Theoretical concern due to immune system effects

Monitoring Recommendations

• Baseline and periodic health assessments
• Cancer screening before and during use
• Monitor for any unusual symptoms
• Discontinue if adverse effects occur

Drug Interactions

Limited data suggests potential interactions with:

• Chemotherapy agents (based on animal studies with cyclophosphamide)
• Other peptide bioregulators may have additive effects

Stacking

Vilon is commonly stacked with other peptide bioregulators developed by the same research group, as they may have complementary mechanisms of action.

Synergistic Combinations

Vilon + Epithalon:

• Complementary anti-aging mechanisms
• Different targets within cellular aging pathways
• Common cycling protocols work well together
• Dosing: Standard doses of each can be combined

Vilon + Thymalin:

• Both are Khavinson bioregulators
• May support different organ systems
• Can be administered together
• Dosing: Use standard protocols for each

Vilon + Cortagen:

• Potential cardiovascular and general anti-aging synergy
• Different primary targets
• Compatible administration schedules

Administration Considerations

• Can be mixed in the same injection when using subcutaneous route
• Oral combinations should maintain empty stomach timing
• Maintain cycling protocols for all components
• Monitor for enhanced effects when combining multiple bioregulators

Timing Protocols

• Morning administration often preferred for bioregulators
• Can be split between morning and evening doses
• Maintain consistent timing for optimal results
• Cycle breaks should apply to entire stack

Note: Vilon is not approved for human use. This information is for research and educational purposes only. Consult healthcare providers before considering any peptide protocols.

References

1. Inhibitory effect of peptide vilon on the development of induced rat urinary bladder tumors in rats. (2001). Bulletin of experimental biology and medicine. DOI PubMed
2. Studies of the effects of Vilon and Epithalon on gene expression in mouse heart using DNA-microarray technology. (2002). Bulletin of experimental biology and medicine. DOI PubMed
3. Anti-aging peptide bioregulators induce reactivation of chromatin. (2006). Georgian medical news. PubMed
4. Effect of peptide Vilon on the content of transforming growth factor-beta and permeability of microvessels during experimental chronic renal failure. (2005). Bulletin of experimental biology and medicine. DOI PubMed
5. Bioregulator Vilon-induced reactivation of chromatin in cultured lymphocytes from old people. (2004). Biogerontology. DOI PubMed
6. EPIGENETIC MODIFICATION UNDER THE INFLUENCE OF PEPTIDE BIOREGULATORS ON THE "OLD" CHROMATIN. (2023). Georgian medical news. PubMed
7. [Combined effect of vilon and cyclophosphane on tumor transplants and lymphoid tissue explants in mice and rats of various age]. (2003). Advances in gerontology = Uspekhi gerontologii. PubMed
8. Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. (2002). International journal of cancer. DOI PubMed
9. Peptide bioregulators inhibit apoptosis. (2000). Bulletin of experimental biology and medicine. PubMed
10. Effect of vilon on biological age and lifespan in mice. (2000). Bulletin of experimental biology and medicine. DOI PubMed